Premium
Salivary gland carcinoma in children and adolescents: The EXPeRT/PARTNER diagnosis and treatment recommendations
Author(s) -
Surun Aurore,
Schneider Dominik T.,
Ferrari Andrea,
StachowiczStencel Teresa,
Rascon Jelena,
Synakiewicz Anna,
Agaimy Abbas,
Martinova Kata,
Kachanov Denis,
Roganovic Jelena,
Bien Ewa,
Bisogno Gianni,
Brecht Ines B.,
Kolb Frédéric,
Thariat Juliette,
MoyaPlana Antoine,
Orbach Daniel
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29058
Subject(s) - medicine , salivary gland , pediatrics , pediatric surgeon , treatment modality , adjuvant therapy , paediatric surgery , intensive care medicine , pathology , surgery , pediatric surgery , chemotherapy
Salivary gland carcinomas (SGCs) are rare during childhood and adolescence. Consequently, no standardized recommendations for the diagnosis and therapeutic management of pediatric SGC are available, and pediatric oncologists and surgeons generally follow adult guidelines. Complete surgical resection with adequate margins constitutes the cornerstone of treatment. However, the indications and modalities of adjuvant therapy remain controversial and may be challenging in view of the potential long‐term toxicities in the pediatric population. This paper presents the consensus recommendations for the diagnosis and treatment of children and adolescents with SGCs, established by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) within the EU‐funded PARTNER project (Paediatric Rare Tumours Network ‐ European Registry).